Trials / Sponsors / Kyowa Kirin Pharmaceutical Development Ltd

Kyowa Kirin Pharmaceutical Development Ltd

Industry · 13 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Active Not Recruiting	Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) Mycosis Fungoides and Sézary Syndrome	—	2022-11-09
Completed	A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth X-Linked Hypophosphatemia	—	2021-11-24
Completed	A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH X-Linked Hypophosphataemia	—	2021-04-01
Completed	Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Y X-linked Hypophosphatemia (XLH)	Phase 1 / Phase 2	2020-02-26
Completed	Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH X-linked Hypophosphatemia	Phase 3	2019-03-07
Completed	Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. Opioid Induced Constipation	—	2018-08-16
Recruiting	Registry for Patients With X-Linked Hypophosphatemia X-Linked Hypophosphatemia	—	2017-09-12
Terminated	Naloxegol Health Outcome Post Authorisation Safety Study Opioid Induced Constipation	—	2016-09-01
Completed	Naloxegol Drug Utilization Post Authorisation Safety Study Opioid Induced Constipation	—	2015-08-01
Completed	Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients Constipation, Signs and Symptoms, Digestive	Phase 1	2014-11-01
Completed	Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years Chemotherapy Induced Nausea and Vomiting	Phase 1	2012-05-01
Withdrawn	Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years Chemotherapy Induced Nausea and Vomiting	Phase 1	—
Withdrawn	Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years Chemotherapy Induced Nausea and Vomiting	Phase 1	—